Kornimate/medical-research-clean huggingface dataset:
mammography, early detection biomarkers, risk assessment, and imaging technologies, merit study

Conditions: Breast Carcinoma

Summary: this study collects mammogram images, blood samples, and clinical information from women undergoing routine screening mammograms. creating a bank of blood samples and a database of clinical and risk information may be used in future research related to breast cancer, other cancers, and women's health.

primary objectives: i. to establish a longitudinal cohort (n=10,000) of women who undergo routine annual mammography screening with follow-up for at least five years for each study participant or until breast cancer diagnosis. ii. to create a repository of blood specimens from the cohort to use for biomarker discovery and validation. iii. to create a comprehensive integrated database of imaging, clinical data, health measurements, and questionnaire data on the study participants. outline: participants complete questionnaires over 15-25 minutes about personal and family history of cancer, health status, breast cancer risk factors, diet, weight gain, and physical activity, and undergo collection of blood samples at baseline and then annually for 5 years. participants also undergo standard of care mammography at baseline and then annually for 5 years.

Eligibility criteria:
inclusion criteria: * willingness to participate in the study and ability to provide informed consent * willingness to complete a questionnaire and to provide a blood sample at the initial visit and at follow up annual visits * undergoing a screening mammogram at participating sites. subjects undergoing routine annual diagnostic mammograms or cem as part of a screening study are also eligible. exclusion criteria: * current or recent (within the prior 6 months) history of breast feeding * personal history of breast cancer (ductal breast carcinoma in situ \[dcis\] or invasive breast cancer) * personal history of any other cancer (excluding in-situ, stage 0, and non-melanoma skin cancers and other pre-cancerous conditions) treated within the last 5 years.
effectiveness and safety of gordian surgical's troclose1200™

Conditions: Hernia

Summary: the use of the troclose1200™ will be done in at least one 12mm planned access port per the troclose1200™ instruction for use. the procedure will be performed routinely. adverse events and device malfunctions, if any, will be recorded. subjects will be hospitalized in accordance with the hospital guidance. all subjects will be followed at 2 weeks (+/- 4 days), at 6 weeks (+/- 1 week), at 12 months (+/- 1 month) and at 24 months (+/- 2 months) in which healing, signs of hernia and adverse events will be recorded. in the 12 and 24 months visit, the hernia signs will be evaluated by ultrasound.

subjects that sign the informed consent form will be evaluated for eligible for the study per eligibility criteria. subject medical background and underlying disease requiring intervention will be taken at screening. procedure will be scheduled. subjects that will eventually, for any reason, will not be operated with the troclose1200™, will be considered as "screen failures". the use of the troclose1200™ will be done in at least one 12mm planned access port per the troclose1200™ instruction for use. the procedure will be performed routinely. duration of use of the troclose1200™ each time it is used will be measured, as well as the entire procedure duration, and the type of procedure. adverse events and device malfunctions, if any, will be recorded. the video seen in the monitors during the procedure will be kept as source data for any further analysis. the location of the troclose1200™ used, as well as the other trocars used location, will be drawn on a special chart. subjects will be hospitalized in accordance with the hospital guidance. all subjects will be followed at 2 weeks (+/- 4 days), at 6 weeks (+/- 1 week), at 12 months (+/- 1 month) and at 24 months (+/- 2 months) in which healing, signs of hernia and adverse events will be recorded. in the 12 and 24 months visit, the hernia signs will be evaluated by ultrasound.

Eligibility criteria:
inclusion criteria: 1. subject is ≥ 18 years old and less than 65 years. 2. subject is a candidate for laparoscopic surgery with at least one 12 mm trocar is to be used apart from the endoscopic access port. 3. subject is capable and willing to comply with, and be present at, the follow-up clinic visits of the 6 weeks visit. 4. subject is able and willing to sign a written informed consent form. exclusion criteria: 1. patients presenting factors that affect the scarring process, such as malnutrition (serum proteins \<5 g/dl or albumin below 3 g/dl). 2. advanced cancer. 3. perioperative hemodynamic instability

Keywords: fascia closure device, hernia,
effectiveness of ziprasidone for patients with schizophrenia

Conditions: Schizophrenia; Schizoaffective Disorder

Summary: this study is designed with the aim to evaluate the clinical effect of the overlapped switching to ziprasidone as well as the efficacy and safe metabolic profile of ziprasidone.

patients with schizophrenia or schizoaffective disorder were recruited in this 12-week, multicenter, non-comparative, open-label trial. prior antipsychotics were allowed to be maintained for up to 4 weeks during the titration of ziprasidone. efficacy was primarily measured using the 18-item brief psychotic rating scale (bprs) at baseline, 4 weeks, 8 weeks, and 12 weeks. efficacy was secondarily measured by the clinical global impression - severity (cgi-s) scale and the global assessment of functioning (gaf) scale at each visit. regarding the metabolic effects of switching to ziprasidone, weight, body mass index (bmi), waist-to-hip ratio (whr), and lipid profile-including triglyceride (tg), high-density lipoprotein (hdl), low-density lipoprotein (ldl), and total cholesterol levels-were measured at each follow-up visit.

Eligibility criteria:
inclusion criteria: * male and female aged 18-55 years treated with risperidone, olanzapine, amisulpride, quetiapine and typical antipsychotics. * both in- and outpatients who met diagnostic and statistical manual of mental disorders (dsm-iv) criteria for schizophrenia or schizoaffective disorder. * their primary psychiatric clinician determined that they would benefit from a change in their medications, either because of suboptimal efficacy or because of side effects. exclusion criteria: * those who are treated with medications that prolong the qtc interval. * those who have any other axis i dsm-iv diagnoses. * those who have a history of substance abuse or dependence within 1 month. * those who have clinically significant abnormal laboratory values or any other abnormal baseline laboratory findings considered by psychiatrists to be indicative of conditions that might affect the study results. * those who have a past history of hypersensitivity or intolerance to ziprasidone. * those who have history of clozapine use within 1 month. * those who participated in clinical trials within 1 month before entering the study entry. * those who have used depot antipsychotics within one cycle before entering the study. * those who are pregnant or are breast feeding. * those who have a immediate risk of harming self or others or history of suicide attempts in the year before the screening precluded inclusion in the study. * the patients unable/unlikely to comprehend/follow the protocol.

Keywords: schizophrenia schizoaffective disorder ziprasidone switch metabolic syndrome
study of the impact of a physical activity programme on the quality of life of patients with inflammatory bowel disease

Conditions: Crohn Disease Haemorrhagic Rectocolitis

Summary: regular physical activity at a mild to moderate intensity can control inflammation in general and intestinal inflammation in particular during ibd. the effectiveness of a physical activity programme has been evaluated during ibd, but the data are limited to a few studies. overall, pa improves quality of life but also improves control of disease symptoms and fatigue . the aim of the present work is to evaluate the impact of a physical activity programme on quality of life in patients with ibd. this programme will also evaluate the impact of physical activity on 1) anxiety-depression, 2) fatigue (a frequent and difficult to manage symptom in ibd), 3) ibd activity, 4) smoking cessation.

crohn's disease and haemorrhagic rectocolitis are chronic inflammatory bowel diseases (cibd) which evolve by flare-ups interspersed with periods of remission . the incidence of these two diseases is increasing in france in adults but also and especially in children and adolescents. indeed, according to data from the epimad registry, from 1988-1990 to 2009-2011, a significant increase in the incidence of both crohn's disease and haemorrhagic rectocolitis was observed in adolescents (10-16 years): for crohn's disease from 4.2 to 9.5/10 5 (+126%; p \<0.001) and for uc from 1.6 to 4.1/10 5 (+156%; p \<0.001). over the long term, crohn's disease can progress to intestinal destruction that can be complicated by stricture(s), obstruction(s), fistula(s) and/or abscesses leading to surgical treatment estimated at 50% after 10 years of crohn's disease progression 1. anti-tnfα therapies are widely prescribed for crohn's disease because they control symptoms, heal the mucosa, reduce hospital admissions and improve quality of life. however, they are associated with side effects often reported by patients, such as asthenia, weight gain and joint pain, symptoms that could be improved by regular physical activity. regular physical activity at a mild to moderate intensity can control inflammation in general and intestinal inflammation in particular during ibd. the effectiveness of a physical activity programme has been evaluated during ibd, but the data are limited to a few studies. overall, pa improves quality of life but also improves control of disease symptoms and fatigue . the aim of the present work is to evaluate the impact of a physical activity programme on quality of life in patients with ibd. this programme will also evaluate the impact of physical activity on 1) anxiety-depression, 2) fatigue (a frequent and difficult to manage symptom in ibd), 3) ibd activity, 4) smoking cessation.

Eligibility criteria:
inclusion criteria: * patient followed for ibd in the hospital of montfermeil * over 18 years of age * medical certificate authorising the practice of physical activity * informed consent exclusion criteria: * age \< 18 years * medical contraindication to physical activity * objection to participation in this study

Keywords: physical activity quality of life
effect of cholesterol level on postoperative acute kidney injury of non-cardiac surgeries

Conditions: Acute Kidney Injury

Summary: preoperative serum cholesterol level may influence occurrence of postoperative acute kidney injury of cardiac surgeries. however, the effect of preoperative serum cholesterol level for non cardiac surgery remains unknown. this study aimed to explore the effect in non-cardiac surgical population.


Eligibility criteria:
inclusion criteria: adults elective non-cardiac surgery exclusion criteria: cardiac surgeries kidney surgeries obstetric surgeries local infiltration anesthesia perioperative data missing
brain and peripheral electrical stimulation in chronic low back pain: a factorial design

Conditions: Chronic Low Back Pain

Summary: the purpose of this study is to evaluate the efficacy of brain and peripheral electrical stimulation on chronic non-specific low back pain patients.


Eligibility criteria:
inclusion criteria: * males and females aged \> 18 years and \<65 years * complaining of back pain for more than three months * presence of a chronic pain measurable with the number rating scale (nrs 0-10) not less than 4 during a 1 week daily nrs monitoring * seeking care for low back pain exclusion criteria: * previous surgery on the spine, spondylolisthesis * previous treatment with tens \<6 months * previous treatment with tdcs * disc herniation with nerve compression * neurological, psychiatric and rheumatologic diseases * impaired sensibility * use of pacemakers or other implanted devices * pregnancy
the effect of analgesic modalities on long term outcomes following open liver resection

Conditions: Liver Cancer

Summary: the liver (local infiltration versus epidural after liver resection) and liver 2 (local infiltration versus epidural after liver resection 2) studies were randomised controlled trials that compared epidural analgesia with local anaesthetic wound infiltration as post-operative analgesia in patients undergoing open liver resection. the overall findings of this trial were of similar rates of morbidity and pain control post-operatively but a reduced recovery time for the wound catheter group. as a result, wound catheter local anesthetic infiltration has become increasingly utilized in this unit and within other units throughout the country and worldwide. epidural use has been associated with improved long term outcomes following abdominal cancer surgery. this study is therefore a long term follow up study of the liver and liver 2 trials to assess survival between the two groups.

the liver and liver 2 studies were randomised controlled trials that compared epidural analgesia with local anaesthetic wound infiltration as post-operative analgesia in patients undergoing open liver resection. the overall findings of this trial were of similar rates of morbidity and pain control post-operatively but a reduced recovery time for the wound catheter group. as a result, wound catheter local anesthetic infiltration has become increasingly utilized in this unit and within other units throughout the country and worldwide. there has been some evidence however, that epidural analgesia post-operatively can have a positive impact on long term survival in patients undergoing abdominal surgery for cancer. the reasons for this are not well established but it is proposed that the protective effect against the immunosuppression following major surgery that epidural has can aid in the cancer prevention process. there remains no randomised controlled trials looking at this subject in open liver surgery. the aim of this study is to assess the overall and disease free survival of the patients who participated in the liver and liver 2 trials. the primary outcome is 5 year overall survival. data will be observed from electronic (or non electronic) patient records, information and statistics department data and general practice records as required. overall survival at 1 and 3 years disease free survival at 1, 3 and 5 years (data will be observed from lothian hepatobiliary multi-disciplinary team meeting data and follow up ct/mri scan dates) median overall and disease free survival survival according to individual pathology subgroups. participants will be identified from study records of the liver and liver 2 trials. this will be performed by the two study investigators.

Eligibility criteria:
inclusion criteria: * patients who participated in the liver and liver 2 trials who had diagnoses of a malignancy and underwent liver resection for this malignancy. exclusion criteria: * patients who had liver resection for benign disease. patients who participated in the liver/liver2 trials but who did not undergo resection.
a retrospective, observational, non-interventional trial to assess eculizumab treatment effect in patients with atypical hemolytic uremic syndrome (ahus)

Conditions: Atypical Hemolytic Uremic Syndrome (aHUS)

Summary: the objective of this retrospective trial is to assess safety and efficacy of eculizumab in ahus patients treated outside of an alexion-sponsored controlled clinical trial.


Eligibility criteria:
inclusion criteria: 1. male or female patients of any age who have been diagnosed with ahus. 2. received at least one dose of eculizumab for the treatment of ahus between 2007 and 2009 outside of an alexion sponsored controlled clinical trial. exclusion criteria: 1. patients who have participated or are currently participating in a controlled clinical trial of eculizumab
a study to explore personalized treatment for patients with recurrent gynecological malignancies based on mtb

Conditions: Ovarian Cancer Recurrent; Endometrial Cancer Recurrent; Cervical Cancer Recurrent

Summary: this is a non-interventional, real-world study divided into two parts: a retrospective study and a prospective study. the main question it aims to answer is: will genomic sequencing and molecular tumor boards lead to clinical responses in patients with recurrent ovarian, cervical, or endometrial cancer? the retrospective arm will analyze data from patients with recurrent gynecological malignancies (ovarian, cervical, or endometrial) who underwent multidisciplinary consultations at our institution from january 2022 onward. data collected will include tumor tissue genomic sequencing results, medical histories, multidisciplinary consultation recommendations, and subsequent treatment courses. this analysis will examine the implementation and clinical efficacy of personalized targeted therapies guided by molecular tumor profiling and multidisciplinary consultation. the prospective arm will enroll 200 patients with recurrent gynecological malignancies (ovarian, cervical, or endometrial) referred for multidisciplinary consultation. tumor tissue and blood samples will undergo next-generation sequencing (ngs) to determine molecular tumor profiles. a multidisciplinary expert panel will formulate individualized treatment strategies based on these profiles, patient clinical data, and treatment history. attending physicians will determine the final treatment plan, integrating multidisciplinary recommendations with patient preferences, comorbidity considerations, drug toxicity assessments, insurance coverage for off-label medications, and the availability of investigational drug trials. this arm aims to observe and evaluate the clinical efficacy of personalized treatment plans developed through molecular tumor profiling and multidisciplinary consultation.


Eligibility criteria:
inclusion criteria: * patients with recurrent ovarian, cervical, or endometrial cancer referred for multidisciplinary consultation by a gynecological oncologist; * presence of at least one evaluable lesion; * willingness to participate in multidisciplinary consultation; * age 18 years or older; * sufficient tumor tissue for next-generation sequencing (ngs) with a tumor content greater than 32%; * informed consent provided by the participant, indicating understanding of the study procedures and willingness to participate. exclusion criteria: * patients with concurrent malignancies; * pregnant patients.

Keywords: genomic sequencing molecular tumor boards recurrent ovarian cancer recurrent endometrial cancer recurrent cervical cancer
safety and feasibility of pulmonary surgery marker system in the intraoperative localization of small pulmonary nodules

Conditions: Lung Neoplasms

Summary: as the detection of small pulmonary nodules continuously grows, the intraoperative localization of small pulmonary nodules is in great demand. the intraoperative localization nowadays is usually done under local anesthesia before surgery. there is a certain rate of failure and complication. the result of our early animal experiments show that the pulmonary surgery marker system can deliver the intraoperative localization safely and precisely under anesthesia, and the average distance between the localization and the simulated lesion is less than 5mm during surgery. therefore, the safety and feasibility of the system require further evaluation in patients

this is a prospective, single-center clinical trial initiated by the investigator. lungbrella marker can be accurately implanted into a predetermined position in the lung assisted by jedivision software and successfully marked the pulmonary nodules which needs to undergo video-assisted thoracoscopic surgery. the study is expected to enroll 10 patients. finally, the effectiveness and safety of the method will be evaluated. this method not only can complete pulmonary nodule localization in the operating room without occupying the resources of radiology department, but also can let patients receive pulmonary nodule location after anesthesia. thereby the risks during transportation are avoided and the suffering of patients is reduced.

Eligibility criteria:
inclusion criteria: subjects should meet all of the following criteria * diagnosis of pulmonary nodule, single nodule operation to be performed and nodule to be located by the decision of chief surgeon. * commit to follow the research procedures and cooperate with the implementation of the whole process research * 1 / 3 of pulmonary nodules are located in the periphery of the lung * signed informed consent with date exclusion criteria: * the target lesion is close to the hilar or large blood vessels * subjects with fev1 less than 1.2 in lung function * subjects with cardiac function iii and cardiac function iv (nyha, new york) * subjects with uncontrollable acute pleura infection * patients with previous history of thoracic surgery (thoracotomy), plural infection, and plural thickening and adhesion on the affected side * other factors that investigators disagree enrollment.

Keywords: lung neoplasm localization of lung nodules ground glass opacity
observational study about in-patients admitted with fever

Conditions: Fever

Summary: fever is a common symptom in patients with infectious diseases. this study hopes to understand the epidemiological characteristics of patients hospitalized due to fever through observational research, including: clinical characteristics, etiology of fever and prognosis after treatment. so as to further search for biochemical or other serological indicators to predict the diagnosis and prognosis of infectious fever and non-infectious fever, and try to establish relevant prediction models.

this study mainly prospectively analyze the clinical data of patients with fever with/without other symptoms admitted to the department of infectious diseases, xiangya hospital of central south university, to analyze the epidemiological characteristics, diagnosis and prognosis of these patients. this is an observational study. all subjects will receive the currently recognized routine test of fever according to their disease and corresponding etiological treatment if needed. the researchers will collect various clinical examination indexes of the subjects in the process of diagnosis and treatment, including but not limited to white blood cells, c-reactive protein, procalcitonin, ferritin, blood culture, therapeutic drugs, etc. etiology and prognosis of patients will be recorded. blood samples, urine and stool samples of all subjects will be taken after enrollment and stored for probably testing in the future. this study has no additional intervention and treatment for subjects. all subjects will sign informed consent.

Eligibility criteria:
inclusion criteria: * all patients admitted to department of infectious diseases because of fever exclusion criteria: * patents who refuse to sign informed consent